Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide vs Dulaglutide in T2D (DREAMS-2)
NCT05606913Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in type 2 diabetes mellitus (T2DM), sponsored by Innovent Biologics. Started Jan 2023; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05606913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606913.